|
1
|
Pui CH, Schrappe M, Ribeiro RC and
Niemeyer CM: Childhood and adolescent lymphoid and myeloid
leukemia. Hematology Am Soc Hematol Educ Program. 118–145. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
August KJ, Narendran A and Neville KA:
Pediatric relapsed or refractory leukemia: New pharmacotherapeutic
developments and future directions. Drugs. 73:439–461. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Konopleva MY and Jordan CT: Leukemia stem
cells and microenvironment: Biology and therapeutic targeting. J
Clin Oncol. 29:591–599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Konopleva M, Tabe Y, Zeng Z and Andreeff
M: Therapeutic targeting of microenvironmental interactions in
leukemia: Mechanisms and approaches. Drug Resist Updat. 12:103–113.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tavor S and Petit I: Can inhibition of the
SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol.
20:178–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peled A and Tavor S: Role of CXCR4 in the
pathogenesis of acute myeloid leukemia. Theranostics. 3:34–39.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pillozzi S, Masselli M, De Lorenzo E,
Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M,
Basso G, et al: Chemotherapy resistance in acute lymphoblastic
leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Blood. 117:902–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li H, Du YM, Guo L, Jie S, Zhang S, Du W,
Chen X, Liu W, Fan L, Zhu J, et al: The role of hERG1 K+
channels and a functional link between hERG1 K+ channels
and SDF-1 in acute leukemic cell migration. Exp Cell Res.
315:2256–2264. 2008. View Article : Google Scholar
|
|
9
|
Pillozzi S, Brizzi MF, Balzi M, Crociani
O, Cherubini A, Guasti L, Bartolozzi B, Becchetti A, Wanke E,
Bernabei PA, et al: HERG potassium channels are constitutively
expressed in primary human acute myeloid leukemias and regulate
cell proliferation of normal and leukemic hemopoietic progenitors.
Leukemia. 16:1791–1798. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pillozzi S, Brizzi MF, Bernabei PA,
Bartolozzi B, Caporale R, Basile V, Pegoraro L, Becchetti A and
Arcangeli A: VEGFR-1 (FLT-1), β1 integrin, and hERG
K+ channel for a macromolecular signaling complex in
acute myeloid leukemia: Role in cell migration and clinical
outcome. Blood. 110:1238–1250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Erdem M, Tekiner TA, Fejzullahu A, Akan G,
Anak S, Saribeyoglu ET, Ozbek U and Atalar F: herg1b expression as
a potential specific marker in pediatric acute myeloid leukemia
patients with HERG 897K/K genotype. Pediatr Hematol Oncol.
32:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pillozzi S, Accordi B, Rebora P, Serafin
V, Valsecchi MG, Basso G and Arcangeli A: Differential expression
of hERG1A and hERG1B genes in pediatric acute lymphoblastic
leukemia identifies different prognostic subgroups. Leukemia.
28:1352–1355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Redfern WS, Carlsson L, Davis AS, Lynch
WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT,
Wallis R, et al: Relationships between preclinical cardiac
electrophysiology, clinical QT interval prolongation and torsade de
pointes for a broad range of drugs: evidence for a provisional
safety margin in drug development. Cardiovasc Res. 58:32–45. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vandenberg JI, Perry MD, Perrin MJ, Mann
SA, Ke Y and Hill AP: hERG K+ channels: Structure,
function, and clinical significance. Physiol Rev. 92:1393–1478.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gasparoli L, D'Amico M, Masselli M,
Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A,
Mitcheson JS, et al: New pyrimido-indole compound CD-160130
preferentially inhibits the KV11.1B isoform and produces
antileukemic effects without cardiotoxicity. Mol Pharmacol.
87:183–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spoo AC, Lübbert M, Wierda WG and Burger
JA: CXCR4 is a prognostic marker in acute myelogenous leukemia.
Blood. 109:786–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fecteau JF, Messmer D, Zhang S, Cui B,
Chen L and Kipps TJ: Impact of oxygen concentration on growth of
mesenchymal stromal cells from the marrow of patients with chronic
lymphocytic leukemia. Blood. 121:971–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sison EA, McIntyre E, Magoon D and Brown
P: Dynamic chemotherapy-induced upregulation of CXCR4 expression: A
mechanism of therapeutic resistance in pediatric AML. Mol Cancer
Res. 11:1004–1016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baba M, Takashima K, Miyake H, Kanzaki N,
Teshima K, Wang X, Shiraishi M and Iizawa Y: TAK-652 inhibits
CCR5-mediated human immunodeficiency virus type 1 infection in
vitro and has favorable pharmacokinetics in humans. Antimicrob
Agents Chemother. 49:4584–4591. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nichols WG, Steel HM, Bonny T, Adkison K,
Curtis L, Millard J, Kabeya K and Clumeck N: Hepatotoxicity
observed in clinical trials of aplaviroc (GW873140). Antimicrob
Agents Chemother. 52:858–865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hachet-Haas M, Balabanian K, Rohmer F,
Pons F, Franchet C, Lecat S, Chow KY, Dagher R, Gizzi P, Didier B,
et al: Small neutralizing molecules to inhibit actions of the
chemokine CXCL12. J Biol Chem. 283:23189–23199. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bernini A, Henrici De Angelis L, Morandi
E, Spiga O, Santucci A, Assfalg M, Molinari H, Pillozzi S,
Arcangeli A and Niccolai N: Searching for protein binding sites
from Molecular Dynamics simulations and paramagnetic fragment-based
NMR studies. Biochim Biophys Acta. 1844:561–566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trott O and Olson AJ: AutoDock Vina:
Improving the speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J Comput
Chem. 31:455–461. 2010.PubMed/NCBI
|
|
24
|
Zhou N, Luo Z, Luo J, Liu D, Hall JW,
Pomerantz RJ and Huang Z: Structural and functional
characterization of human CXCR4 as a chemokine receptor and HIV-1
co-receptor by mutagenesis and molecular modeling studies. J Biol
Chem. 276:42826–42833. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu B, Chien EY, Mol CD, Fenalti G, Liu W,
Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al: Structures
of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide
antagonists. Science. 330:1066–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gozansky EK, Louis JM, Caffrey M and Clore
GM: Mapping the binding of the N-terminal extracellular tail of the
CXCR4 receptor to stromal cell-derived factor-1alpha. J Mol Biol.
345:651–658. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Veldkamp CT, Seibert C, Peterson FC, De la
Cruz NB, Haugner JC III, Basnet H, Sakmar TP and Volkman BF:
Structural basis of CXCR4 sulfotyrosine recognition by the
chemokine SDF-1/CXCL12. Sci Signal. 1:ra42008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Costantini S, Raucci R, De Vero T,
Castello G and Colonna G: Common structural interactions between
the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural
ligands, CXCL11 and CXCL12, by a modeling approach. Cytokine.
64:316–321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Irwin JJ, Sterling T, Mysinger M, Bolstad
ES and Coleman RG: ZINC: A free tool to discover chemistry for
biology. J Chem Inf Model. 52:1757–1768. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Veldkamp CT, Ziarek JJ, Peterson FC, Chen
Y and Volkman BF: Targeting SDF-1/CXCL12 with a ligand that
prevents activation of CXCR4 through structure-based drug design. J
Am Chem Soc. 132:7242–7243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Konopleva M, Konoplev S, Hu W, Zaritskey
AY, Afanasiev BV and Andreeff M: Stromal cells prevent apoptosis of
AML cells by up-regulation of anti-apoptotic proteins. Leukemia.
16:1713–1724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng Z, Samudio IJ, Munsell M, An J, Huang
Z, Estey E, Andreeff M and Konopleva M: Inhibition of CXCR4 with
the novel RCP168 peptide overcomes stroma-mediated chemoresistance
in chronic and acute leukemias. Mol Cancer Ther. 5:3113–3121. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rashidi A and DiPersio JF: Targeting the
leukemia-stroma interaction in acute myeloid leukemia: Rationale
and latest evidence. Ther Adv Hematol. 7:40–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Estey E and Döhner H: Acute myeloid
leukemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Colmone A, Amorim M, Pontier AL, Wang S,
Jablonski E and Sipkins DA: Leukemic cells create bone marrow
niches that disrupt the behavior of normal hematopoietic progenitor
cells. Science. 322:1861–1865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lagneaux L, Delforge A, Bron D, De Bruyn C
and Stryckmans P: Chronic lymphocytic leukemia B cells but not
normal B cells are rescued from apoptosis by contact with normal
bone marrow stromal cells. Blood. 91:2387–2396. 1998.PubMed/NCBI
|
|
38
|
Pillozzi S, Masselli M, Gasparoli L,
D'Amico M, Polletta L, Veltroni M, Favre C, Basso G, Becchetti A
and Arcangeli A: Macrolide antibiotics exert antileukemic effects
by modulating the autophagic flux through inhibition of hERG1
potassium channels. Blood Cancer J. 6:e4232016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beider K, Begin M, Abraham M, Wald H,
Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, et al:
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple
myeloma tumor growth. Exp Hematol. 39:282–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Patel S, Abdelouahab H, Wittner
M, Willekens C, Shen S, Betems A, Joulin V, Opolon P, Bawa O, et
al: CXCR4 inhibitors selectively eliminate CXCR4-expressing human
acute myeloid leukemia cells in NOG mouse model. Cell Death Dis.
3:e3962012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Uy GL, Rettig MP, Stone RM, Konopleva MY,
Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades
W, et al: A phase 1/2 study of chemosensitization with plerixafor
plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood
Cancer J. 7:e5422017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Parameswaran R, Yu M, Lim M, Groffen J and
Heisterkamp N: Combination of drug therapy in acute lymphoblastic
leukemia with a CXCR4 antagonist. Leukemia. 25:1314–1323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Boyle G, Swidenbank I, Marshall H,
Barker CE, Armstrong J, White SA, Fricker SP, Plummer R, Wright M
and Lovat PE: Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by
AMD11070. Br J Cancer. 108:1634–1640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feng Z, Dubyak GR, Jia X, Lubkowski JT and
Weinberg A: Human β-defensin-3 structure motifs that are important
in CXCR4 antagonism. FEBS J. 280:3365–3375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Beider K, Darash-Yahana M, Blaier O,
Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O,
Peled A, et al: Combination of imatinib with CXCR4 antagonist
BKT140 overcomes the protective effect of stroma and targets CML in
vitro and in vivo. Mol Cancer Ther. 13:1155–1169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Abraham M, Klein S, Bulvik B, Wald H,
Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, et al:
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by
downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered
miR-15a/16-1 expression. Leukemia. 31:2336–2346. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kashyap MK, Kumar D, Jones H,
Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR,
Sabbatini P, Cohen LJ, et al: Ulocuplumab (BMS-936564 / MDX1338): A
fully human anti-CXCR4 antibody induces cell death in chronic
lymphocytic leukemia mediated through a reactive oxygen
species-dependent pathway. Oncotarget. 7:2809–2822. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Das D, Maeda K, Hayashi Y, Gavande N,
Desai DV, Chang SB, Ghosh AK and Mitsuya H: Insights into the
mechanism of inhibition of CXCR4: identification of
Piperidinylethanamine analogs as anti-HIV-1 inhibitors. Antimicrob
Agents Chemother. 59:1895–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
